VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...
Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...
While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...
What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback